VWR Corporation (NASDAQ:VWR) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.

VWR has been the topic of several other reports. Zacks Investment Research lowered shares of VWR Corporation from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. ValuEngine upgraded shares of VWR Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $31.67.

VWR Corporation (NASDAQ:VWR) last issued its quarterly earnings data on Monday, July 31st. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.45 by $0.04. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the business posted $0.42 EPS. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/13/vwr-corporation-vwr-downgraded-by-bidaskclub-to-strong-sell.html.

A number of institutional investors and hedge funds have recently made changes to their positions in VWR. Bank of New York Mellon Corp increased its stake in VWR Corporation by 5.7% during the 1st quarter. Bank of New York Mellon Corp now owns 465,569 shares of the medical research company’s stock worth $13,129,000 after buying an additional 25,026 shares during the period. UBS Asset Management Americas Inc. increased its stake in VWR Corporation by 42.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 65,313 shares of the medical research company’s stock worth $1,842,000 after buying an additional 19,528 shares during the period. Karp Capital Management Corp purchased a new stake in VWR Corporation during the 1st quarter worth approximately $758,000. Sei Investments Co. increased its stake in VWR Corporation by 17.2% during the 1st quarter. Sei Investments Co. now owns 24,336 shares of the medical research company’s stock worth $687,000 after buying an additional 3,567 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in VWR Corporation by 7.3% during the 1st quarter. Ameriprise Financial Inc. now owns 49,824 shares of the medical research company’s stock worth $1,405,000 after buying an additional 3,374 shares during the period.

About VWR Corporation

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.

Receive News & Stock Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related stocks with our FREE daily email newsletter.